Acute myeloid leukemia

Innate Pharma Third Quarter 2021 Report

Retrieved on: 
Tuesday, November 16, 2021

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.
  • ET)
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following dial in numbers:
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • In September and November 2021, Innate also presented at the ESMO 2021 and SITC conferences respectively.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)

Retrieved on: 
Monday, November 15, 2021

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML.
  • GlycoMimetics reiterates its guidance that, based upon current projections, it expects topline results after year-end 2022.
  • As a potential first-in-class therapeutic that selectively disrupts extrinsic pathways of chemoresistance, we believe uproleselan can be transformative for AML patients, commented Harout Semerjian, GlycoMimetics Chief Executive Officer.
  • GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia, and inflammatory diseases with high unmet need.

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Retrieved on: 
Monday, November 15, 2021

This was a transformational quarter for LAVA, said Stephen Hurly, president and chief executive officer.

Key Points: 
  • This was a transformational quarter for LAVA, said Stephen Hurly, president and chief executive officer.
  • LAVA-051 Phase 1/2a Trial on Track: Enrollment is ongoing in the Phase 1/2a clinical trial ( NCT04887259 ) evaluating LAVA-051 in hematological malignancies.
  • The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-051.
  • LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

Retrieved on: 
Friday, November 12, 2021

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.
  • Research and development expenses for the three months ended September 30, 2021, increased $12.5 million compared to the prior year period.
  • Net income for the third quarter of 2021 was $49.9 million, or $0.47 per share (basic) and $0.40 per share (diluted).
  • If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

Retrieved on: 
Friday, November 12, 2021

ImCheck is presenting these updates in addition to two posters covering ICT01 at SITC.

Key Points: 
  • ImCheck is presenting these updates in addition to two posters covering ICT01 at SITC.
  • The conference is taking place in Washington, D.C. and virtually, from November 10 - 14, 2021.
  • All posters presented in the poster hall will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 12, 2021

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .

Key Points: 
  • NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .
  • (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.
  • Pipeline Update and Corporate Highlights:
    Additional sites in the United States and European Union were activated during the third quarter with enrollment continuing.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Friday, November 12, 2021

The data were presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting titled Mesothelin (MSLN) targeting allogeneic CAR-T cells engineered to overcome tumor immunosuppressive microenvironment.

Key Points: 
  • The data were presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting titled Mesothelin (MSLN) targeting allogeneic CAR-T cells engineered to overcome tumor immunosuppressive microenvironment.
  • The poster presentation highlighted the following preclinical data:
    Mesothelin is an interesting target for CAR-T cell therapy for solid tumors because it is highly and consistently expressed in mesothelioma and pancreatic cancers.
  • It is also over-expressed in subsets of other solid tumors (ovarian cancer, non-small cell lung cancer, gastric cancer, triple-negative breast cancer) while modestly expressed in healthy cells, indicating that targeting mesothelin may result in a safe and effective therapy.
  • It is the first TALEN-induced triple knock out (KO) product candidate in the allogeneic CAR-T space.

Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event

Retrieved on: 
Friday, November 12, 2021

As part of the virtual event, the Company will provide a brief presentation, followed by a moderated Roundtable discussion and an interactive Q&A session.

Key Points: 
  • As part of the virtual event, the Company will provide a brief presentation, followed by a moderated Roundtable discussion and an interactive Q&A session.
  • In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event.
  • Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com .
  • A live video webcast of the Roundtable Event will be available on the Events page of the Investors section of the Company's website ( moleculin.com ).

Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML

Retrieved on: 
Friday, November 12, 2021

AIRPORT CITY, Israel, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The multi-center study will be conducted across 18 leading U.S. and Israeli sites including Memorial Sloan Kettering Cancer Center and The University of Texas MD Anderson Cancer Center.

Key Points: 
  • The initiation of this multi-center, U.S. based, Phase 2 study is an important step forward in the development of aspacytarabine, seeking to address unmet needs in the treatment of patients with relapsed or refractory AML and MDS.
  • Patients with relapsed or refractory AML and MDS have limited treatment options and poor prognoses, with many patients unable to tolerate intensive chemotherapy.
  • Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
  • Aspacytarabine is currently being investigated as a single agent in a Phase 2b clinical trial, which recently completed enrollment, for the first-line treatment of AML.

Chimerix to Present at Jefferies London Healthcare Conference

Retrieved on: 
Friday, November 12, 2021

An audio webcast of the presentation will be available on the Investor Relations section ofChimerix'swebsite at ir.chimerix.com , where it will be archived for approximately 90 days.

Key Points: 
  • An audio webcast of the presentation will be available on the Investor Relations section ofChimerix'swebsite at ir.chimerix.com , where it will be archived for approximately 90 days.
  • Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT).